A Model of the Cost Effectiveness of Infliximab for the Treatment of Severely Active Ulcerative Colitis, in Children and Adolescents Aged 6 to 17 Years, Who Have Had an Inadequate Response to Conventional Therapy

✍ Scribed by Farrell, J.; Jiang, Y.; Chaudhary, M.A.; Sheppard, O.; Gathany, T.; Fan, T.

• Book ID: 122176803
• Publisher: John Wiley and Sons
• Year: 2013
• Tongue: English
• Weight: 58 KB
• Volume: 16
• Category: Article
• ISSN: 1098-3015
• DOI: 10.1016/j.jval.2013.08.1501